Nick Mitrokostas Discusses New Biosimilar Approval and the Outlook for 2020

June 21, 2020

In this episode of Not So Different, we sat down with Nick Mitrokostas, an intellectual property (IP) lawyer and partner at Goodwin's IP Litigation group, to discuss how the approval of Pfizer’s pegfilgrastim biosimilar (Nyvepria) will affect the biosimilar market and what he sees for the rest of 2020.

Recently, Pfizer announced its pegfilgrastim biosimilar (Nyvepria) was approved by the FDA, which marks the first biosimilar approval this year. Although many expected more approvals earlier in the year, experts wonder if the race to find a revolutionary treatment and vaccine for coronavirus disease 2019 (COVID-19) slowed down the approval process and biosimilars have had to take a back seat for the time being.

We sat down with Nick Mitrokostas, an intellectual property lawyer and partner at Goodwin's IP Litigation group, to discuss how this new approval will affect the biosimilar market and what he sees for the rest of 2020.

To learn more about the approval of Nyvepria, check out our article on it here.

To learn more about Goodwin Proctor LLP, visit goodwinlaw.com